Clinical trials: Chemotherapy-induced Nausea and Vomiting (CINV)
Chemotherapy-Induced Nausea and Vomiting (CINV)
Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV
This study is a prospective, single-arm, multicenter, exploratory clinical trial divided into a screening phase, a treatment phase, and a follow-up phase.
- Trial name
- NCT07726433
- Testing
- Fosrolapitant and Palonosetron Hydrochloride for Injection
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Chemotherapy-induced Nausea and Vomiting
Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy
This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in subjects receiving MEC.
- Trial name
- NCT01500226
- Testing
- Rolapitant, Granisetron, Dexamethasone
- Where
- United States
- Volunteers
- 1,369 people
- Sponsor
- Tesaro, Inc.
Chemotherapy-induced Nausea and Vomiting
Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants
The purpose of this research study is to see if olanzapine helps to prevent nausea and/or vomiting (throwing up) when it is added to other medicines in subjects having stem cell transplants.
- Trial name
- NCT04535141
- Testing
- Olanzapine 5 MG
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Nausea, Vomiting
Laser Acupuncture Against Nausea in Children
To investigate whether nonthermal low level laser acupuncture has beneficial effects on nausea and vomiting in children receiving highly emetogenic chemotherapy for a malignant solid tumor.
- Conditions
- Nausea, Vomiting, Cancer
- Trial name
- NCT00528554
- Testing
- laser acupuncture
- Where
- 2 sites in Germany
- Volunteers
- 25 people
- Sponsor
- University Children Hospital Homburg
Chemotherapy-induced Nausea and Vomiting
To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)
To study the safety and effectiveness of a granisetron patch to treat Chemotherapy-Induced Nausea and Vomiting (CINV)
- Trial name
- NCT00273468
- Testing
- Granisetron
- Volunteers
- 630 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chemotherapy-induced Nausea and Vomiting
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intravenous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion…
- Trial name
- NCT03403712
- Testing
- fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
- Where
- 40 sites in United States, Georgia
- Volunteers
- 404 people
- Sponsor
- Helsinn Healthcare SA
Nausea, Vomiting
The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting
This study is a three group, randomized, double blind, placebo-controlled trial with two repeated measurements. The same measurements will be collected for each participant during two consecutive chemotherapy treatment…
- Trial name
- CINV (NCT04478630)
- Testing
- Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Milton S. Hershey Medical Center
Chemotherapy-induced Nausea and Vomiting (CINV)
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
Transdermal granisetron has been shown to as effective as oral/ intravenous granisetron when administered with or without dexamethasone.
- Trial name
- NCT04912271
- Testing
- Granisetron transdermal patch, Palonosetron, Aprepitant
- Volunteers
- 140 people
- Sponsor
- Fudan University
Oncology, Breast Cancer
Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy
This study explores whether a commonly used medication called Pantoprazole can help prevent delayed nausea and vomiting from chemotherapy for early breast cancer.
- Conditions
- Oncology, Breast Cancer, Chemotherapy-induced Nausea and Vomiting
- Trial name
- PantoCIN (NCT03948477)
- Testing
- Pantoprazole 40mg
- Where
- 10 sites in New Zealand
- Volunteers
- 160 people
- Sponsor
- University of Auckland, New Zealand
Complications of Bone Marrow Transplant, Hematologic Neoplasms
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
The objective of this study is to compare the effectiveness of olanzapine added to standard triplet therapy (fosaprepitant, ondansetron, and dexamethasone) versus triplet therapy alone in preventing chemotherapy-induced nausea…
- Trial name
- FOND-O (NCT02635984)
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Augusta University
Breast Cancer
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
This is a prospective, multicenter, open label, non-comparative trial in Spain. The primary objective of this study is to determine the complete response, defined as no vomiting and no use of rescue treatment, in women with…
- Trial name
- NCT01298193
- Testing
- Aprepitant
- Where
- 13 sites in Spain
- Volunteers
- 212 people
- Sponsor
- Spanish Breast Cancer Research Group
Nausea, Vomiting
Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV)
The management of chemotherapy-induced nausea and vomiting (CINV) has evolved in recent years and became less frequent. CINV include early (occurring within 24 hours of chemotherapy administration) and delayed (occurring within 4…
- Trial name
- NVCI (NCT02767791)
- Testing
- Acupuncture, Auriculotherapy
- Where
- 5 sites in France
- Volunteers
- 116 people
- Sponsor
- Hopital Foch
Chemotherapy-induced Nausea and Vomiting
Granisetron Transdermal Patch System for Prevention of CINV by CapeOX
This study aims to explore the prevention of delayed chemotherapy induced by CAPOX regimen with granisetron transdermal patch。
- Trial name
- NCT05325190
- Testing
- Granisetron Transdermal Patch System
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Nausea and Vomiting, Chemotherapy-Induced
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
This is a Phase III trial designed to demonstrate that casopitant when added to dexamethasone and ondansetron is more effective in the prevention of vomiting then dexamethasone and ondansetron alone, in patients who receive a…
- Trial name
- NCT00431236
- Testing
- Oral Casopitant (GW679769), IV Casopitant (GW679769), IV ondansetron hydrochloride
- Where
- 80 sites in Argentina, Belgium and 20 more
- Volunteers
- 810 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial
The object of this study is to evaluate the superiority of aprepitant therapy with a 5HT3-receptor antagonist, dexamethasone and aprepitant compared to standard therapy with a 5HT3-receptor antagonist and dexamethasone for…
- Trial name
- NCT01344304
- Testing
- Aprepitant / Fosaprepitant
- Where
- 27 sites in Japan
- Volunteers
- 413 people
- Sponsor
- Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
Brain Cancer
Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab
1. Primary Objective: To determine the efficacy and tolerability of palonosetron and dexamethasone in preventing acute CINV in brain tumor patients during the first 24 hours of receiving Irinotecan /Bevacizumab regimens. 2.
- Trial name
- NCT00636805
- Testing
- Palonosetron (Aloxi) and Dexamethasone
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Duke University
Chemotherapy-Induced Nausea and Vomiting (CINV)
Evaluating the Feasibility and Acceptability of Inhalation Aromatherapy for Patients Undergoing Autologous Haematopoietic Stem Cell Transplant (HSCT)
The goal of this clinical trial is to evaluate whether aromatherapy inhaler sticks can reduce nausea and vomiting in patients receiving chemotherapy as part of their stem cell transplant treatment.
- Trial name
- Aroma-CINV (NCT07209501)
- Testing
- Aromatherapy inhaler
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore General Hospital
Chemotherapy-Induced Nausea and Vomiting, Lung Cancer
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
Aprepitant is an oral neurokinin-1(NK-1) antagonist which is used for the prevention of chemotherapy-induced nausea and vomiting (CINV).
- Trial name
- NCT02445872
- Testing
- Aprepitant, Palonosetron, Dexamethasone
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang University
Liver Cancer, Liver Metastasis
Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin
Objectives: This protocol is part of a larger grant funded by the NCI to create an international research center to study Traditional Chinese Medicine (TCM).
- Trial name
- NCT00430313
- Testing
- Electro-Stimulation of Yongquan (K1) Acupoint
- Sponsor
- M.D. Anderson Cancer Center
Nausea With Vomiting Chemotherapy-Induced
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3 receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy induced nausea or vomiting (CINV).
- Trial name
- NCT04592198
- Testing
- Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Xiamen LP Pharmaceutical Co., Ltd